Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06579300 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT06579300 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 72 participants.
The verdict
NCT06579300, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study will assess the safety, tolerability, and pharmacokinetics of ABBV-1088 in healthy adult Western, Han-Chinese and Japanese participants. This study will also assess drug-drug interaction between itraconazole and ABBV-1088 in healthy adult Western participants.
Interventions
- DRUG Itraconazole (ITZ)
- DRUG ABBV-1088
- DRUG Placebo for ABBV-1088
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-09-04 |
| Est. Completion | 2025-09-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06579300
The ClinicalTrials.gov registry entry for NCT06579300 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Itraconazole (ITZ) is the first listed.
NCT06579300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06579300 about?
NCT06579300 is a clinical study titled "A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088". This study will assess the safety, tolerability, and pharmacokinetics of ABBV-1088 in healthy adult Western, Han-Chinese and Japanese participants. This study will also assess drug-drug interaction between itraconazole and ABBV-1088 in healthy adult Western participants.
What is the current status of trial NCT06579300?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2024-09-04. Estimated completion is 2025-09-03.
What interventions are being tested in trial NCT06579300?
The interventions under investigation include: Itraconazole (ITZ) (DRUG), ABBV-1088 (DRUG), Placebo for ABBV-1088 (DRUG).
Who is sponsoring clinical trial NCT06579300?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.